A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 17 May 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 17 May 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2019.
- 20 Jan 2017 New trial record